Sanofi ( (SNY) ) has provided an announcement.
In March 2025, Sanofi announced its acquisition of Dren Bio’s bispecific myeloid cell engager, DR-0201, for $600 million upfront, with potential future payments of $1.3 billion. This acquisition aims to enhance Sanofi’s immunology pipeline by leveraging DR-0201’s ability to induce deep B-cell depletion, which could reset the immune system and offer treatment-free remission for autoimmune diseases. The transaction, expected to close in Q2 2025, positions Sanofi as a leader in immunology, addressing unmet medical needs in autoimmune conditions such as lupus.
More about Sanofi
Sanofi is a global healthcare company focused on transforming medicine by providing life-changing treatment options and vaccines. The company is dedicated to improving lives through scientific innovation and is committed to sustainability and social responsibility. Sanofi is a leader in the immunology sector and is listed on EURONEXT and NASDAQ.
YTD Price Performance: 21.60%
Average Trading Volume: 2,545,752
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $147.3B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com